Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Children's Hospital of Philadelphia
City of Hope Medical Center
University of Chicago
Penn State University
City of Hope Medical Center
Seattle Children's Hospital
Essen Biotech
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Princess Maxima Center for Pediatric Oncology
Seattle Children's Hospital
Jonsson Comprehensive Cancer Center
Princess Maxima Center for Pediatric Oncology
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Thomas Jefferson University
Thomas Jefferson University
M.D. Anderson Cancer Center
Stanford University
Assiut University
Princess Maxima Center for Pediatric Oncology
M.D. Anderson Cancer Center
Ain Shams University
University of Nebraska
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Jewish General Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Memorial Sloan Kettering Cancer Center
Technical University of Munich
Therapeutic Advances in Childhood Leukemia Consortium
H. Lee Moffitt Cancer Center and Research Institute
University of Florida
Memorial Sloan Kettering Cancer Center
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
Shenzhen University General Hospital
Banc de Sang i Teixits
Shanghai Jiao Tong University School of Medicine
M.D. Anderson Cancer Center